New drug and biological product approvals, 2010

Traynor, Kate
February 2011
American Journal of Health-System Pharmacy;2/1/2011, Vol. 68 Issue 3, p186
Academic Journal
The article presents the drugs which received the marketing approval from the U.S. Food & Drug Administration (FDA). It includes the Tocilizumab or Actemra which is used for treating moderate to severe rheumatoid arthritis, the Pradaxa oral thrombin inhibitor, and the tesamorelin or Egrifta for treating abdominal lipodystrophy. It includes the Dalfampridine which is used for treating multiple sclerosis (MS) symptom.


Related Articles

  • No Strings Attached. Peters, Rita C. // Drug Discovery & Development;May2012, Vol. 15 Issue 5, p4 

    The author discusses the implications of the reauthorization of the Prescription Drug User Fee Act (PDUFA) in the U.S. She explains that the legislation must be renewed before its expiration date on September 30, 2012 because it may compromise the drug review process and may force the Food and...

  • 2010 Pharmaceutical Approvals.  // American Journal of Health-System Pharmacy;2/1/2011, Vol. 68 Issue 3, p188 

    The article presents the 2010 approved drugs in the U.S. It includes the Alcaftadine ophthalmic solution treatment for allergic conjunctivitis, the Carglumic acid tablets use for treating acute hyperammonemia caused by the deficiency of N-acetylglutamate synthase (NAGS), and Dabigatran etexilate...

  • The Food and Drug Administration Amendments Act and Postmarketing Commitments. Fain, Kevin; Daubresse, Matthew; Alexander, G. Caleb // JAMA: Journal of the American Medical Association;7/10/2013, Vol. 310 Issue 2, p202 

    The article focuses on a study which examined the changes associated with post-marketing studies that are required for a prescription drug's approval and adherence by the U.S. Food and Drug Administration (FDA) as per the Food and Drug Administration Amendments Act (FDAAA) of 2007. It further...

  • The Complexities of Litigating Generic Drug Exclusion Claims in the Antitrust Class Action Context. Royall, M. Sean; Lipton, Joshua // Antitrust Magazine;Spring2010, Vol. 24 Issue 2, p22 

    The article focuses on the complexities involved in litigating generic drug exclusion claims made by the branded pharmaceutical manufacturers under the U.S. antitrust law. It discusses the Hatch-Waxman Act which permits a generic manufacturer to file an Abbreviated New Drug Application, to be...

  • FDA suggests new user-fee programs for drugmakers.  // Modern Healthcare;1/16/2012, Vol. 42 Issue 3, p4 

    The article reports on the proposals sent by the U.S. Food and Drug Administration (FDA) to the U.S. Congress concerning the two user-free schemes for drug manufacturers that would help pay for faster evaluations of their generic and biosimilar drugs applications.

  • FDA Designations for Therapeutics and Their Impact on Drug Development and Regulatory Review Outcomes. Kesselheim, AS; Darrow, JJ // Clinical Pharmacology & Therapeutics;Jan2015, Vol. 97 Issue 1, p29 

    New prescription drugs receive approval from the US Food and Drug Administration (FDA) based on tests establishing safety and adequate and well-controlled trials demonstrating 'substantial evidence' of efficacy. However, a number of legislative and regulatory initiatives, the most recent being...

  • FDA Approvals & Regulations: Guide to Critical Analysis.  // Points of View: FDA Approvals & Regulations;3/1/2016, p4 

    The article offers a critical guide to the issue of U.S. Food and Drug Administration (FDA) approvals and regulations. The article discusses criteria in understanding the issue, such as distinguishing between fact and opinion and recognizing point and counterpoint arguments. Also presented are...

  • The FDA approves Somatuline(r) Depot (lanreotide) Injection Extended Dosing Interval as part of Ipsen's Prior Approval Supplement application.  // Biomedical Market Newsletter;3/31/2011, p162 

    The article reports on the approval given by the U.S. Food and Drug Administration (FDA) for the extension of dosing interval of Ipsen's Somatuline Depot for patients with acromegaly. It explains that FDA's approval permits patients with acromegaly to extend dosing intervals for up to eight...

  • In Opposition to Liberty: We Need a “Sovereign” to Govern Drug Claims. Avorn, Jerry // Annals of Internal Medicine;8/4/2015, Vol. 163 Issue 3, p229 

    The author comments on the plans of the U.S. Food and Drug Administration (FDA) to hold a public meeting to discuss whether its restrictions on drug manufacturers' claim about their products infringes their liberty. Topics discussed include need for FDA to allow companies to review the available...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics